- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
In spite of criticism, Lilly saves lives
March 30, 2009
Steven J.My wife, Becky, is alive today because of Lilly and its trial drug Enzastaurin, a great surgeon, and a terrific team of local
doctors.
MoreExecutives make many trips to Washington to argue for 14 years of sales exclusivity for new drugs made from cells
March 23, 2009
J.K. WallEli Lilly & Co. executives are making many trips to Washington to argue for 14 years of sales exclusivity for new drugs made
from cells.
MoreLilly relying on technology to spot management talent
March 2, 2009
Scott OlsonAn electronic succession-planning system created by Eli Lilly & Co. about seven years ago is sniffing out top talent.
MoreAre we victims of 'group think'?
February 16, 2009
John Guy"Group think," a powerful and controlling force, was present as the Capital Improvement Board built Lucas Oil Stadium and
Eli Lilly and Co. developed and marketed Zyprexa.
MoreHealth care interests wary of state's cost-cutting idea for Medicaid
February 9, 2009
J.K. WallIndiana Medicaid officials want to take over management of all its patients' prescription drugs because they say it could
save the state as much as $40 million a year.
MoreBiotech push may help offset generic competition; some analysts skeptical
February 2, 2009
J.K. WallLilly executives want to make biotech their top focus.
MoreLilly settles Zyprexa marketing suit for $1.4 billion
January 15, 2009
J.K. WallIndianapolis-based Lilly pleaded guilty to one violation of the Food, Drug and Cosmetic Act on Thursday and agreed to pay
$1.42 billion to settle both that criminal charge as well as civil lawsuits in which it did not admit wrongdoing.
MoreLilly eyes generic biotech drugs
January 5, 2009
Generic drugmakers have been the nemesis of companies like Eli Lilly and Co., but now the Indianapolis-based company and its
peers want to get in the generic game
themselves.
MoreLilly makes $6.5B acquisition
December 29, 2008
J.K. WallEli Lilly and Co. CEO John Lechleiter played a game of pharmaceutical poker with former Lilly Chief Financial Officer Jim
Cornelius—and won.
MoreGeneric meds cost more than consumers realize
December 15, 2008
Generic drug makers drive up the cost of name-brand drugs developed by locally based Eli Lilly and Co. and other pharmaceutical
firms.
MoreLilly fighting with generic drug firms over Cymbalta, Alimta, 5 other medications
December 8, 2008
J.K. WallEli Lilly & Co. has filed lawsuits against seven generic drug companies in federal court in Indianapolis, asking a judge to
declare its Cymbalta patent valid and to tell the generic companies to back off.
MoreEli Lilly investing $100M in China, hoping to attract research partners
December 1, 2008
Brian SpegeleHoping to increase sales in China's rapidly growing pharmaceutical market, Eli Lilly and Co. is charging ahead
with
plans to invest $100 million in venture capital in the region over the next several years.
MoreLilly buys ImClone as part of strategy to capitalize on cancer-drug market
October 13, 2008
J.K. WallEli Lilly and Co. has written a $6.5 billion IOU to acquire the cancer drugs of ImClone Systems Inc. Cancer drugs are now the best-selling class of drugs in the world and one of the fastest growing.
Lilly taps hedge fund to cut research costs for Alzheimer's drugs
August 11, 2008
J.K. WallEli Lilly and Co.'s unorthodox efforts to develop new treatments for Alzheimer's disease--if successful--could usher in a new approach to drug development. The Indianapolis-based pharmaceutical company announced that a New York hedge fund, TPG-Axon Capital, will invest up to $325 million to help cover the exorbitant development costs of two experimental compounds to treat Alzheimer's disease.
Janitors want Lilly, WellPoint to push for better health benefits
April 14, 2008
J.K. WallService Employees International Union Local 3 is backing local janitors as they restart contract negotiations April 16 with
five of the largest janitorial contractors in Indianapolis. SEIU now is taking direct aim at Lilly, health insurer WellPoint
Inc. and even some local hospitals, hoping they will pressure the janitorial contractors to come to terms.
MoreLilly expects FDA approval of long-acting version of Zyprexa
February 4, 2008
J.K. WallEli Lilly and Co. hopes to extend the life of its best-seller Zyprexa with a potentially lucrative, long-acting form of the
antipsychotic drug. But first, the Indianapolis-based drugmaker must win over a panel of medical experts convened by the U.S.
Food and Drug Administration on Feb. 6.
MoreTaurel passes the baton
December 31, 2007
J.K. WallA new leader will guide the city's largest company in 2008, with some of the biggest challenges in its history on the horizon.
Eli Lilly and Co. announced Dec. 18 that CEO Sidney Taurel will step down March 31 and will be replaced by President John
C. Lechleiter, who has been the heir apparent for more than two years.
MoreNew Lilly CEO called analytical, 'incredibly warm'
December 24, 2007
J.K. WallJohn C. Lechleiter, whom Eli Lilly and Co.'s board voted to replace Sidney Taurel as CEO, is known for getting things done
and yet also for being good at analysis and relating to people under him. Taurel will step down at the end of March but remain
chairman until the end of 2008.
MoreTaurel helped Lilly weather Prozac defeat, but he also stumbled
December 24, 2007
J.K. WallWhen Eli Lilly and Co. CEO Sidney Taurel announced his retirement Dec. 18, he said he was leaving the company in good shape.
And he can cite plenty of evidence to support him. But when Taurel steps down as CEO March 31, he also will leave a legacy
of a languishing stock price and some costly mistakes that some think could have been avoided. "The facts are the facts; I
guess you can't ignore it. The stock price has been...
MoreLilly's plan to outsource more work is good news, bad news
December 17, 2007
J.K. WallEli Lilly and Co. will shrink itself with "great intensity" over the next few years, in part by
outsourcing. For other local life sciences firms, that's a fat pitch for new business. But it's not clear if non-Lilly firms
can grow fast enough to offset the jobs and wages Indianapolis will lose from Lilly.
MoreLilly under gun to replace aging blockbuster Zyprexa
November 5, 2007
J.K. WallThere's a $2 billion hole in Eli Lilly and Co.'s future. That's roughly how much pretax profit Lilly derives each year from
its best-seller, Zyprexa, according to calculations by IBJ. And it's how much black ink will start running off Lilly's books
once Zyprexa's U.S. and European patents expire in 2011.
MoreTaurel draws fire for getting rich while stock struggles
May 28, 2007
J.K. WallEli Lilly and Co. stock has returned just 1 percent per year in the nine years since CEO Sidney Taurel took office. Meanwhile,
Taurel has taken home $44 million in pay and been given stock options valued at $114 million more. But most Lilly shareholders
aren't raising a call for Taurel to hit the trail.
MoreLilly still breathing in inhaler pursuit
April 2, 2007
J.K. WallPfizer Inc.'s new inhaled insulin product, Exubera, has stumbled out of the gate. That would appear to keep the door open
for Eli Lilly and Co., as well as for other companies racing to develop inhaled insulin. But Pfizer's troubles might cause
doctors and patients to sour on all inhaled insulin products.
MoreAriad patent victory over Lilly among largest in 2006
January 3, 2007
Eli Lilly and Co.’s loss in May of a patent-infringement lawsuit brought by Ariad Pharmaceuticals
Inc. went down as the 6th-largest such jury award last year, a Bloomberg analysis shows.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
In my opinion the estridge companies are crooks. They filed bankruptcy on their 'track housing' side of the business two weeks before they closed on one of my clients' homes. When my client first interviewed Estridge as a builder 6 months before, they specifically ASKED about the solvency of their business, knowing that some builders were struggling. Estridge truly misrepresented their financial situation at that time. I suppose I am more unhappy with the whole system than I am with the builder because what the heck==you can file bankruptcy on 'track homes' but still keep building and make money off of 'custom built' homes??? How ridiculous! They are all homes. How can a company be allowed to bilk thousands of dollars from their subcontractors but still be allowed to build houses?? they should have been made to pay back all their unpaid contractors before being allowed to profit from building any more houses! This alone makes them and the system crooks in my eyes. I would never build an estridge home and I would not recommend for my clients either. If they were truly 'bankrupt' how could they afford to keep building homes anyway??? The whole system needs fixed.
I live a couple blocks east of the Angie's campus and my house is assessed for ~$160,000. If I could get that amount, let alone $384,000 (a 140% bonus), I'd sell in a minute. Either Angie's stockholders just got fleeced, or Angie's is getting about a 58% discount on their property taxes, if these properties are actually worth what they paid Mr. Oesterle for them. Which do you think is the case?
Perhaps the IMA board is really to blame! They agreed to hire Charles. They can't seemingly find donors among themselves, or bring in new blood that will support the museums operating budget with an expanded museum and money to provide curators with something to do (ie buy art). The headlines of disarray at the museum and mass firings are hurting the reputation of the museum for some time to come. If people on the board had misgivings, perhaps they shpuld have more forcefully opposed efforts that they have seemingly been unable to fund, like expansion and the costs it has created!
See, I told u Indyman and Dipsicle....this 8 days is overkill. It's barely worth a weekend....great job Tony George! Your dream has been fulfilled....he fans want the I r l back. Thats how good it was.....and that sucked.
I have been in training for a short time now but right off I can see that safety and quality are the number one issues, my experience as of late has been a positive one, the employees along with Jeff the plant manager and the operation supervisor as well as the engineers are a highly motivated group of people, what an asset for the area to have and for company's in need of a quality metal products.